Overview
GRCE market data
Price History
GRCE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.31 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,435.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.79 – $5.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $33.7M · P/B 1.12 · P/S 168.34.
Company News
Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) EstimateBenzinga · Aug 13, 2026, 12:23 PM
8-K filing — Grace Therapeutics, Inc. (GRCE)SEC EDGAR · Aug 13, 2026, 12:01 PM
Reported Earlier, Grace Therapeutics Prices Private Placement Of 4,761,904 Shares At $2.10 Per Share To Fund GTx-104 Manufacturing And Regulatory WorkBenzinga · Aug 5, 2026, 6:53 AM
Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy DeficienciesBenzinga · Jul 28, 2026, 11:06 AM
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) EstimateBenzinga · Jun 18, 2026, 1:50 PM